Neurocrine Biosciences, Inc. - Common Stock (NBIX)
166.80
-18.70 (-10.08%)
NASDAQ· Last Trade: Aug 2nd, 5:22 AM EDT
Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The
Via MarketBeat · July 31, 2026
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.
Via The Motley Fool · July 30, 2026
Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setupchartmill.com
Via Chartmill · July 27, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stockchartmill.com
Via Chartmill · July 25, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setupchartmill.com
Via Chartmill · July 20, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screeningchartmill.com
Via Chartmill · July 16, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screenchartmill.com
Via Chartmill · July 11, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screenchartmill.com
Via Chartmill · July 4, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setupchartmill.com
Via Chartmill · July 1, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Frameworkchartmill.com
Via Chartmill · June 24, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentalschartmill.com
Via Chartmill · June 20, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidatechartmill.com
Via Chartmill · June 16, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategychartmill.com
Via Chartmill · June 10, 2026
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Scorechartmill.com
Via Chartmill · June 8, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82chartmill.com
Via Chartmill · June 3, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and Bull Flag Breakout Setupchartmill.com
Via Chartmill · May 29, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Momentum Breakout Setupchartmill.com
Via Chartmill · May 26, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potentialchartmill.com
Via Chartmill · May 22, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentalschartmill.com
Via Chartmill · May 19, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunitychartmill.com
Via Chartmill · May 12, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Smashes Q1 Estimates with 44% Sales Surgechartmill.com
Via Chartmill · May 5, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Qualifies for Affordable Growth Screen with Strong GARP Profilechartmill.com
Via Chartmill · April 30, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setupchartmill.com
Via Chartmill · April 17, 2026
Neurocrine (NBIX) Q1 2026 Earnings Transcript
Via The Motley Fool · May 5, 2026